STAT3 signaling in pulmonary arterial hypertension.
Pulmonary artery hypertension (PAH) is a proliferative disorder associated with enhanced pulmonary artery smooth muscle cell proliferation and suppressed apoptosis. The sustainability of this phenotype requires the activation of pro-survival transcription factor like the signal transducers and activators of transcription-3 (STAT3). Using multidisciplinary and translational approaches, we and others have demonstrated that STAT3 activation in both human and experimental models of PAH accounts for the modulation of the expression of several proteins already known as implicated in PAH pathogenesis, as well as for signal transduction to other transcription factors. Furthermore, recent data demonstrated that STAT3 could be therapeutically targeted in different animal models and some molecules are actually in clinical trials for cancer or PAH treatment.
Vascular Biology Research Group; Department of Medicine; University of Alberta; Edmonton, AB Canada.
Roxane
R
Paulin
Jolyane
J
Meloche
Sébastien
S
Bonnet
STAT3; micro-RNA; oncoproteins; pulmonary hypertension; therapy